Acadian Asset Management
ALLO icon

Acadian Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Acadian Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660K Buy
318,366
+229,747
+259% +$505K ﹤0.01% 1375
2026
Q1 		$214K Sell
88,619
-906,522
-91% -$1.82M ﹤0.01% 1564
2025
Q4 		$1.36M Buy
995,141
+461,332
+86% +$609K ﹤0.01% 1022
2025
Q3 		$659K Buy
533,809
+463,343
+658% +$552K ﹤0.01% 1150
2025
Q2 		$79K Buy
+70,466
New +$93.6K ﹤0.01% 1435
2024
Q1 		– Sell
-84,717
Closed -$271K – 1554
2023
Q4 		$271K Buy
+84,717
New +$240K ﹤0.01% 1172

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Acadian Asset Management's ALLO Position: Q2 2026 in Review

Acadian Asset Management increased its Allogene Therapeutics (ALLO) stake by 259% in Q2 2026, buying an estimated $505K and bringing the position to 318,366 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

Acadian Asset Management first reported a position in ALLO in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.36M in Q4 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Acadian Asset Management held 318,366 shares of Allogene Therapeutics worth $660K as of Q2 2026.
  • Acadian Asset Management bought 229,747 Allogene Therapeutics shares in Q2 2026, an estimated $505K.
  • Allogene Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1375 holding.
  • Acadian Asset Management first reported a position in Allogene Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • Acadian Asset Management's Allogene Therapeutics position peaked at $1.36M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.